Overview of measurements and assessments during the trial
| Baseline | Mid-intervention | Postintervention | Follow-up 1 | Follow-up 2 | |
| Time (weeks) | 0 | 6* | 12* | 24* | 36 |
| Questionnaires | |||||
| CAT | X | X | X | X | X |
| mMRC | X | X | X | X | X |
| CIS | X | X | X | X | X |
| PCFS | X | X | X | X | X |
| Nijmegen | X | X | X | X | X |
| HADS | X | X | X | X | X |
| WPAI | X | X | X | X | X |
| EQ-5D-5L | X | X | X | X | X |
| Patient interview | X | X | X | X | X |
| Vital signs, length and weight | X | X | X | X | |
| Pulmonary evaluation: | |||||
| Spirometry+DLCO+lung volumes | X | X | X | ||
| MIP/MEP | X | X | X | X | |
| Handgrip strength | X | X | X | X | |
| 6MWT | X | X | X | X | |
| Activity tracker | X | X | X | X | |
| Pulmonary evaluation: X-ray-thorax/CT-thorax | X |
Assessments during the baseline visit and 6, 12 and 24 weeks visit will be done at one of the two hospitals mentioned above.
Patients in the intervention group must have started pulmonary rehabilitation within 2 weeks after randomisation.
*Time will start from the date of the first physiotherapy session for the intervention group and the date of randomisation for the control group, considering a range of 2 weeks.
CAT, COPD Assessment Test; CIS, Checklist Individual Strength; DLCO, diffusing capacity for carbon monoxide; EQ-5D-5L, EuroQol-5D-5L; HADS, Hospital Anxiety and Depression Scale; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure; mMRC, modified Medical Research Council Dyspnoea Scale; 6MWT, six-minute walk test; PCFS, post-COVID-19 Functional Status; WPAI, Work Productivity and Activity Impairment Questionnaire.